198 related articles for article (PubMed ID: 23388174)
1. Diabetes and hypercholesterolemia increase blood-brain barrier permeability and brain amyloid deposition: beneficial effects of the LpPLA2 inhibitor darapladib.
Acharya NK; Levin EC; Clifford PM; Han M; Tourtellotte R; Chamberlain D; Pollaro M; Coretti NJ; Kosciuk MC; Nagele EP; Demarshall C; Freeman T; Shi Y; Guan C; Macphee CH; Wilensky RL; Nagele RG
J Alzheimers Dis; 2013; 35(1):179-98. PubMed ID: 23388174
[TBL] [Abstract][Full Text] [Related]
2. Retinal pathology is associated with increased blood-retina barrier permeability in a diabetic and hypercholesterolaemic pig model: Beneficial effects of the LpPLA
Acharya NK; Qi X; Goldwaser EL; Godsey GA; Wu H; Kosciuk MC; Freeman TA; Macphee CH; Wilensky RL; Venkataraman V; Nagele RG
Diab Vasc Dis Res; 2017 May; 14(3):200-213. PubMed ID: 28301218
[TBL] [Abstract][Full Text] [Related]
3. Atherosclerotic plaque inflammation varies between vascular sites and correlates with response to inhibition of lipoprotein-associated phospholipase A2.
Fenning RS; Burgert ME; Hamamdzic D; Peyster EG; Mohler ER; Kangovi S; Jucker BM; Lenhard SC; Macphee CH; Wilensky RL
J Am Heart Assoc; 2015 Feb; 4(2):. PubMed ID: 25672369
[TBL] [Abstract][Full Text] [Related]
4. Brain-reactive autoantibodies prevalent in human sera increase intraneuronal amyloid-β(1-42) deposition.
Nagele RG; Clifford PM; Siu G; Levin EC; Acharya NK; Han M; Kosciuk MC; Venkataraman V; Zavareh S; Zarrabi S; Kinsler K; Thaker NG; Nagele EP; Dash J; Wang HY; Levitas A
J Alzheimers Dis; 2011; 25(4):605-22. PubMed ID: 21483091
[TBL] [Abstract][Full Text] [Related]
5. Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease.
Riley RF; Corson MA
IDrugs; 2009 Oct; 12(10):648-55. PubMed ID: 19790016
[TBL] [Abstract][Full Text] [Related]
6. Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons.
Clifford PM; Zarrabi S; Siu G; Kinsler KJ; Kosciuk MC; Venkataraman V; D'Andrea MR; Dinsmore S; Nagele RG
Brain Res; 2007 Apr; 1142():223-36. PubMed ID: 17306234
[TBL] [Abstract][Full Text] [Related]
7. Evidence that Brain-Reactive Autoantibodies Contribute to Chronic Neuronal Internalization of Exogenous Amyloid-β1-42 and Key Cell Surface Proteins During Alzheimer's Disease Pathogenesis.
Goldwaser EL; Acharya NK; Wu H; Godsey GA; Sarkar A; DeMarshall CA; Kosciuk MC; Nagele RG
J Alzheimers Dis; 2020; 74(1):345-361. PubMed ID: 32039847
[TBL] [Abstract][Full Text] [Related]
8. A Chronic Increase in Blood-Brain Barrier Permeability Facilitates Intraneuronal Deposition of Exogenous Bloodborne Amyloid-Beta1-42 Peptide in the Brain and Leads to Alzheimer's Disease-Relevant Cognitive Changes in a Mouse Model.
Acharya NK; Grossman HC; Clifford PM; Levin EC; Light KR; Choi H; Swanson Ii RL; Kosciuk MC; Venkataraman V; Libon DJ; Matzel LD; Nagele RG
J Alzheimers Dis; 2024; 98(1):163-186. PubMed ID: 38393907
[TBL] [Abstract][Full Text] [Related]
9. Darapladib.
Bui QT; Wilensky RL
Expert Opin Investig Drugs; 2010 Jan; 19(1):161-8. PubMed ID: 20001561
[TBL] [Abstract][Full Text] [Related]
10. Effect of lipoprotein-associated phospholipase A2 inhibitor on insulin resistance in streptozotocin-induced diabetic pregnant rats.
Wang GH; Jin J; Sun LZ
Endocr J; 2018 Sep; 65(9):903-913. PubMed ID: 29925744
[TBL] [Abstract][Full Text] [Related]
11. Darapladib for the treatment of cardiovascular disease.
Campos CM; Suwannasom P; Koenig W; Serruys PW; Garcia-Garcia HM
Expert Rev Cardiovasc Ther; 2015 Jan; 13(1):33-48. PubMed ID: 25521799
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development.
Wilensky RL; Shi Y; Mohler ER; Hamamdzic D; Burgert ME; Li J; Postle A; Fenning RS; Bollinger JG; Hoffman BE; Pelchovitz DJ; Yang J; Mirabile RC; Webb CL; Zhang L; Zhang P; Gelb MH; Walker MC; Zalewski A; Macphee CH
Nat Med; 2008 Oct; 14(10):1059-66. PubMed ID: 18806801
[TBL] [Abstract][Full Text] [Related]
13. Darapladib: an emerging therapy for atherosclerosis.
Corson MA
Ther Adv Cardiovasc Dis; 2010 Aug; 4(4):241-8. PubMed ID: 20660537
[TBL] [Abstract][Full Text] [Related]
14. Reduction in Vasa Vasorum Angiogenesis by Lp-PLA2 Selective Inhibitor Through The HIF-1α and VEGF Expression Under Dyslipidemic Conditions in Atherosclerosis Pathogenesis.
Heriansyah T; Nafisatuzzamrudah N; Aini FN; Ridwan M; Primardhika RF; Wijayanti M; Bekti RS; Wihastuti TA
Cardiovasc Hematol Agents Med Chem; 2018; 16(2):114-119. PubMed ID: 30394217
[TBL] [Abstract][Full Text] [Related]
15. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
16. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice.
LaRue B; Hogg E; Sagare A; Jovanovic S; Maness L; Maurer C; Deane R; Zlokovic BV
J Neurosci Methods; 2004 Sep; 138(1-2):233-42. PubMed ID: 15325132
[TBL] [Abstract][Full Text] [Related]
17. Effect of darapladib treatment on endarterectomy carotid plaque lipoprotein-associated phospholipase A2 activity: a randomized, controlled trial.
Johnson JL; Shi Y; Snipes R; Janmohamed S; Rolfe TE; Davis B; Postle A; Macphee CH
PLoS One; 2014; 9(2):e89034. PubMed ID: 24586490
[TBL] [Abstract][Full Text] [Related]
18. Serum-derived immunoglobulins neutralize adverse effects of amyloid-beta peptide on the integrity of a blood-brain barrier in vitro model.
Poetsch V; Neuhaus W; Noe CR
J Alzheimers Dis; 2010; 21(1):303-14. PubMed ID: 20421696
[TBL] [Abstract][Full Text] [Related]
19. Role of AT1 receptors in permeability of the blood-brain barrier in diabetic hypertensive rats.
Awad AS
Vascul Pharmacol; 2006 Sep; 45(3):141-7. PubMed ID: 16959546
[TBL] [Abstract][Full Text] [Related]
20. High-Density Lipoprotein Mimetic Peptide 4F Efficiently Crosses the Blood-Brain Barrier and Modulates Amyloid-
Swaminathan SK; Zhou AL; Ahlschwede KM; Curran GL; Lowe VJ; Li L; Kandimalla KK
J Pharmacol Exp Ther; 2020 Nov; 375(2):308-316. PubMed ID: 32778535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
